Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme
Open Access
- 1 November 2003
- journal article
- research article
- Published by BMJ in Journal of Medical Genetics
- Vol. 40 (11) , 807-814
- https://doi.org/10.1136/jmg.40.11.807
Abstract
Introduction: Accurate individualised breast cancer risk assessment is essential to provide risk–benefit analysis prior to initiating interventions designed to lower breast cancer risk. Several mathematical models for the estimation of individual breast cancer risk have been proposed. However, no single model integrates family history, hormonal factors, and benign breast disease in a comprehensive fashion. A new model by Tyrer and Cuzick has addressed these deficiencies. Therefore, this study has assessed the goodness of fit and discriminatory value of the Tyrer–Cuzick model against established models namely Gail, Claus, and Ford. Methods: The goodness of fit and discriminatory accuracy of the models was assessed using data from 1933 women attending the Family History Evaluation and Screening Programme, of whom 52 developed cancer. All models were applied to these women over a mean follow up of 5.27 years to estimate risk of breast cancer. Results: The ratios (95% confidence intervals) of expected to observed numbers of breast cancers were 0.48 (0.37 to 0.64) for Gail, 0.56 (0.43 to 0.75) for Claus, 0.49 (0.37 to 0.65) for Ford, and 0.81 (0.62 to 1.08) for Tyrer–Cuzick. The accuracy of the models for individual cases was evaluated using ROC curves. These showed that the area under the curve was 0.735 for Gail, 0.716 for Claus, 0.737 for Ford, and 0.762 for Tyrer–Cuzick. Conclusion: The Tyrer–Cuzick model is the most consistently accurate model for prediction of breast cancer. The Gail, Claus, and Ford models all significantly underestimate risk, although the accuracy of the Claus model may be improved by adjustments for other risk factors.Keywords
This publication has 17 references indexed in Scilit:
- Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast CancerJNCI Journal of the National Cancer Institute, 1999
- Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2The Lancet, 1999
- Validation Studies for Models Projecting the Risk of Invasive and Total Breast Cancer IncidenceJNCI Journal of the National Cancer Institute, 1999
- Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer FamiliesAmerican Journal of Human Genetics, 1998
- Risks of cancer in BRCA1-mutation carriersThe Lancet, 1994
- Autosomal dominant inheritance of early-onset breast cancer. Implications for risk predictionCancer, 1994
- Fortnightly Review: Familial breast cancerBMJ, 1994
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI Journal of the National Cancer Institute, 1989
- Regression Models in Clinical Studies: Determining Relationships Between Predictors and ResponseJNCI Journal of the National Cancer Institute, 1988
- The meaning and use of the area under a receiver operating characteristic (ROC) curve.Radiology, 1982